Cancer heterogeneity, plasticity and resistance to therapies (Canther)
Lille University – Lille University Hospital – Inserm – Institut Pasteur de Lille – CNRS – CLCC Lille – COL
Director : Isabelle Van Seuningen
The main goal of the CANTHER laboratory “CANcer, heterogeneity, plasticity and resistance to THERapies” is to better understand the mechanisms of resistance to cancer treatments. Molecular mechanisms understanding will lead to the discovery of new biomarkers of resistance and new therapeutic strategies in order to propose adapted and better targeted therapies to the cancer patients (precision medicine). In order to reach these goals, CANTHER teams develop a multidisciplinary fundamental and translational research of excellence in the fields of resistance to treatments and tumor dormancy.
The laboratory is a CNRS-Inserm unit (UMR9020 CNRS-U1277 Inserm) composed of 5 teams with specific and complementary expertises, competences and skills in order to answer these scientific goals.
An outstanding scientific, technologic and venue environment
For that, CANTHER benefits from an outstanding scientific, technologic and venue environment as CANTHER is part of the “Interdisciplinary Cancer Research Institute of Lille” entitled ONCOLille and is located within the hospital campus next to the two hospitals. This allows us to develop an outstanding pre-clinical and clinical research in close collaboration with clinicians and clinical departments of both the Lille hospital (CHU Lille) and Regional Center against Cancer Oscal Lambret (COL).
CANTHER being also a Lille Pasteur Institute (IPL) unit, we participate to its scientific and strategic project by developing research on aging and age-related diseases that include cancers.
Finally, CANTHER being a University of Lille unit, we actively participate in the students, university teachers and basic scientists of talent training/recruitment. CANTHER teams are thus participating to the national and international visibility and attractiveness of their institutions.
Efficacy and resistance to anti-tumour therapies
Group leader : David Tulasne
Senescence, fibrosis and cancer
Group leader : Corinne Abbadie
Mucins, cancer and drug resistance
Group leader : Isabelle Van Seuningen
Cellular plasticity and cancer
Group leader : Xuefen Le Bourhis
Persistence factors of leukaemia cells
Group leader : Bruno Quesnel